Little-Known Synthorx Names Former Cleave CEO as New Leader
Shawver, a long-time industry veteran, will assume the role of president, CEO and director of Synthorx. Source: BioSpace
Shawver, a long-time industry veteran, will assume the role of president, CEO and director of Synthorx. Source: BioSpace
On Oct. 6, the FDA approved Flexion Therapeutics' Zilretta for osteoarthritis knee pain and is now in the middle of launching the drug and installing its commercial operations. Source: BioSpace
The company announced that Neutrolis and Remora Therapeutics are the winners of Bristol-Myers Squibb’s 2017 Golden Tickets for LabCentral. Source: BioSpace
The safety profile of avelumab was consistent with that observed in the overall JAVELIN clinical development program. Source: BioSpace
J&J is balking at a plan to build a site in Britain due to concerns over the economy. Source: BioSpace
Gritstone Oncology is hanging a "help wanted" sign as the company looks to staff a new 43,000 square-foot manufacturing facility in Pleasanton, Calif. that will be the center of the…
AM-111 failed to meet its primary endpoint, although the company is putting a positive spin on it by noting it was effective in a subpopulation. Source: BioSpace
Ardelyx will receive a $30 million upfront payment and is eligible to receive additional development and commercialization milestones worth up to $130 million. Source: BioSpace
Clovis Oncology has solidified its physical footprint in the Bay Area with a 32,000 square foot space it secured for 10 years through property developer TMG Partners. Source: BioSpace
The FDA flagged Horizon Pharmaceuticals for failure to follow sanitation procedures, insufficient investigations into customer complaints and inadequate reviews of product discrepancies, among other issues. Source: Drug Industry Daily